Effect of Insulin on von Willebrand Factor Release in Normal and Diabetic Subjects: In Vivo and In Vitro Studies

The aim of this study was to evaluate the effect of insulin on the release of vWf in vivo during an oral glucose tolerance test (OGTT) performed in normal, glucose-intolerant and diabetic subjects and in vitro on human endothelial cells. Twenty-eight subjects exhibiting risk factors for diabetes underwent an OGTT: 11 subjects proved to be normal, 7 were glucose-intolerant and 10 diabetic. In each group, the vWf and PAI-1 plasmatic levels were measured at t = 0, 30 min and 180 min after the beginning of the test. Human endothelial cells from non-diabetic and diabetic subjects were incubated in the presence of human insulin at various concentrations (0.25, 2.5, 25 and 250 mUI/ml). After 1, 4, and 24 hours of incubation, the release of vWf and endothelin 1 was measured in the cell supernatant and the intracellular amount of vWf in the cell lysate. During the OGTT, the vWf levels in plasma were not affected despite a 4.5-, 6-, and 2.5-fold increase in insulin levels in normal, glucose-intolerant and diabetic subjects, respectively. Although raised in all three groups, PAI-1 plasmatic levels remained constant during the test. After 24 hours of exposure to insulin (0.25 mU/ml), the release of vWf by endothelial cells reached 35.94 ± 23.08 % of the basal value for non-diabetic subjects, and 27.57 ± 10.05 % for diabetic patients. Similar results were observed in non-stimulated cells. Insulin had no influence on intracellular vWf content, which remained comparable to control values. Regardless of its concentration, insulin failed to stimulate the release of vWf by endothelial cells of non-diabetic and diabetic subjects, while its ability to stimulate the release of endothelin 1 was preserved. In conclusion, hyperinsulinemia had no adverse effect on circulating vWf in normal or diabetic subjects. Neither release nor intracellular vWf content in non-diabetic or diabetic endothelial cells was influenced by insulin in vitro.

Key words:

Insulin - Diabetes - von Willebrand Factor - Endothelial Cell

References

• 1 Stehouwer Coen D A, Lambert J, Donker A JM, van Hinsbergh V WM. Endothelial dysfunction and pathogenesis of diabetic angiopathy.  Cardiovascular Research. 1997;  34 55-68
• 2 Jager A, Van Hinsbergh V W, Kostense P J, Emeis J J, Yudkin J S, Nijpels G, Dekker J M, Heine R J, Bouter L M, Stehouwer C D. Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and non-diabetic subjects: the Hoorn study.  Arterioscler Thromb Vasc Biol. 1999;  19 3071-3078
• 3 Stehouwer Coen D A, Fisher A HR, Kuijk A WR, Polak B CP, Donker A JM. Endothelial dysfunction precedes development of microalbuminuria in IDDM.  Diabetes. 1995;  44 561-564
• 4 Plater M E, Ford I, Dent M T, Preston F E, Ward J D. Elevated von Willebrant factor antigen predicts deterioration in diabetic peripheral nerve function.  Diabetologia. 1996;  39 336-343
• 5 Mordes D B, Lazarchick J, Colwell J A, Sens D A. Elevated glucose concentrations increase factor VIIIR: Ag levels in human umbilical vein endothelial cells.  Diabetes. 1983;  32 876-878
• 6 Steiner M, Reinhardt K M, Krammer B, Ernst B, Blann A D. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control.  Thrombosis and Haemostasis. 1994;  72 979-984
• 7 Yngen M, Ostensen C G, Li N, Hjemdahl P, Wallen N H. Acute hyperglycemia increases soluble P-selectin in male patients with mild diabetes mellitus.  Blood Coagul Fibrinolysis. 2001;  12 109-116
• 8 Heise T, Heinemann L, Kristahn K, Berger M, Sawicki P T. Insulin sensitivity in patients with essential hypertension: no influence of the ACE inhibitor enalapril.  Horm Metab Res. 1999;  31 418-423
• 9 Pinkney J H, Stehouwer C D, Coppack S W, Yudkin J S. Endothelial dysfunction: cause of the insulin resistance syndrome.  Diabetes. 1997;  46 9-13
• 10 Metsärinne K, Saijonmaa O, Yki-Järvinen H, Fyhrquist F. Insulin increases the release of endothelin in endothelial cell cultures in vitro but not in vivo. .  Metabolism. 1994;  43 878-882
• 11 Ferri C, Pittoni V, Piccoli A, Laurenti O, Cassone M R, Bellini C, Properzi G, Valesini G, De Mattia G, Santucci A. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulated its circulating levels in vivo. .  J Clin Endocrinol Metab. 1995;  80 829-835
• 12 Yasuko I, Toshimitsu O, Yasufumi S, Morio I, Toshiie S. Plasminogen activator inhibitor-1 in nonobese subjects with non-insulin-dependent diabetes mellitus.  P.S.E.B.M.. 1996;  211 287-291
• 13 Conlan M G, Folsom A R, Finch A, Finch A, Davis C E, Sorlie P, Marcucci G, Wu K K. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis.  Thrombosis and Haemostasis. 1993;  70 380-385
• 14 Van Wachem P A, Reinders J H, van Buul-Wortelboer M F, de Groot P G, van Aken W G, van Mourik J A. Von Willebrand factor in cultured human vascular endothelial cells from adult and umbilical cord arteries and veins.  Thrombosis and Haemostasis. 1986;  56 189-385
• 15 Jaffe E A, Nachman R L, Becker C G, Minick C R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.  The journal of clinical investigation. 1973;  52 2747-2756
• 16 Azimzadeh A, Wolf P, Thibaudeau K, Cinqualbre J, Soulillou J P, Anegon I. Comparative study of target antigens for primate xenereactive natural antibodies in pig and rat endothelial cells.  Transplantation. 1997;  64 1166-1174
• 17 Meigs J B, Mittleman M A, Nathan D M, Tofler G H, Singer D E, Murphy-Sheehy P M, Lipinska I, D'Agostino R B, Wilson P W. Hyperunsulinema, hyperglycemia and impaired hemostasis: the framingham offspring study.  JAMA. 2000;  283 221-228
• 18 Mcgill J B, Schneider D J, Arfken C L, Lucore C L, Sobel B E. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients.  Diabetes. 1994;  43 104-109
• 19 Blann A D, McCollum C N. Adverse influence of cigarette smoking on the endothelium.  Thrombosis and Haemostasis. 1993;  70 707-711
• 20 Blann A D, Bushell D, Davies A, Faragher E B, Miller J P, McCollum C N. Von Willebrand factor, the endothelium and obesity.  Int J Obesity. 1993;  17 723-725
• 21 Vischer U M, Emeis J J, Bilo H JG, Stehouwer C DA, Thomsen C, Rasmussen O, Hermansen K, Wolheim C B, Ingerslev J. Von Willebrand factor (vWf) as a plasma marker of endothelial activation in diabetes: improved reliability with parallel determination of the vWf propeptide (vWf/AgII).  Thrombosis and Haemostasis. 1998;  80 1002-1006
• 22 Heywood D M, Mansfield M W, Grant P J. Levels of von Willebrand factor, insulin resistance syndrome and a common vWf gene polymorphism in non-insulin-dependant (type 2) diabetes mellitus.  Diab Med. 1996;  13 720-725
• 23 Jilma B, Dallinger S, Hergovich N, Eichler H G, Richter V, Wagner O F. Effects of hyperinsulinemia on plasma levels of circulating adhesion molecules.  J Clin Endocrinol Metab. 2000;  85 1748-1751
• 24 Seligman B GS, Biolo A, Polanczyk C A, Gross J L, Clausell N. Increased plasma levels of endothelin-1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia.  Diabetes Care. 2000;  23 1395-1400
• 25 Albertini J P, Valensi P, Lormeau B. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment.  Diabetes Care. 1998;  21 1008-1013
• 26 Hattori R, Hamilton K K, McEver R P, Sims P J. Complement proteins C5b-9 Induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface.  J Biol Chem. 1989;  264 9053-9060
• 27 Hu R M, Levin E R, Pedram A, Franck H J. Insulin stimulates production and secretion of endothelin from bovine endothelial cells.  Diabetes. 1993;  42 351-358
• 28 Desideri G, Ferri C, Bellini C, De Mattia G, Santucci A. Effects of ACE inhibition on spontaneous and insulin-stimulated endothelin-1 secretion: in vitro and in vivo studies.  Diabetes. 1997;  46 81-86
• 29 Ribau J CO, Samis J A, Senis A Y, Maurice D H, Giles A R, DeReske M, Absher P M, Hatton M WC, Richardson M. Aortic endothelial cell von Willebrand factor content and circulating plasminogen activator inhibitor-1 are increased but expression of endothelial leucocyte adhesion molecules is unchanged in insulin-dependent diabetic BB rats.  Atherosclerosis. 2000;  149 331-342
• 30 Boeri D, Cagliero E, Podesta F, Lorenzi M. Vascular wall von Willebrand factor in human diabetic retinopathy.  Invest Ophthalmol Vis Sci. 1994;  90 1558-1564